Androstenedione is the preferred androgen source in hormone refractory prostate cancer--letter

Nima Sharifi1, Richard J Auchus2

  • 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. sharifn@ccf.org.

Abstract

No abstract available in PubMed .

Related Concept Videos